LoginSignup
Gilead Sciences logo

Gilead Sciences

Stock
Stock
ISIN: US3755581036
Ticker: GILD
US3755581036
GILD

Price

Price

CHART BY

Historical dividends and forecast

All dividend data

 The next dividend will be paid on 28.03.2025

$2.515

CHART BY

Frequently asked questions

What is Gilead Sciences's market capitalization?

The market capitalization of Gilead Sciences is $137.03B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is Gilead Sciences's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for Gilead Sciences is 289.34. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for Gilead Sciences?

Gilead Sciences's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $0.371. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Gilead Sciences's stock?

Currently, 33 analysts cover Gilead Sciences's stock, with a consensus target price of $108.67. Analyst ratings provide insights into the stock's expected performance.

What is Gilead Sciences's revenue over the trailing twelve months?

Over the trailing twelve months, Gilead Sciences reported a revenue of $28.74B.

Is Gilead Sciences paying dividends?

Yes, Gilead Sciences is paying dividends. The next payment is scheduled for 28.03.2025, with an expected amount of .

What is the free float of Gilead Sciences's shares?

The free float of Gilead Sciences is 1.24B. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$137.03B
EPS (TTM) 
$0.371
Free Float 
1.24B
P/E ratio (TTM) 
289.34
Revenue (TTM) 
$28.74B

Pricing

1D span
$109.18$111.13
52W span
$62.07$111.02

Analyst Ratings

The price target is $108.67 and the stock is covered by 33 analysts.

Buy

21

Hold

11

Sell

1

Information

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Industries
Biotechnology
Sector
Health Care

Identifier

ISIN
US3755581036
Primary Ticker
GILD

Knockouts

Finance data from FactSet
Join the conversation
Sign upLogin